Lyell Immunopharma Inc (NASDAQ:LYEL) currently has a daily average trading volume of 1.06M but it saw 2030646 shares traded in last market. With a market cap of 312.32M USD, the company’s current market price of $1.22 came falling about -17.57 while comparing to the previous closing price of $1.48. In past 52 weeks, the stock remained buoying in the range of price level as high as $3.26 and as low as $0.85. In the recent trading on the day, stock has struck highest price mark of $1.1601 while lowest mark touched by it was $1.47.
Taking a look at 20-day trading activity of Lyell Immunopharma Inc (LYEL) gives us an average price of $1.1305, while its current price level is -62.53% below from 52-week high level whereas it is 43.53% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.2322 while that of 200 days or SMA-200 reads an average of $1.8674. A closer look into the stock’s movement over the week reveals that its volatility is standing at 23.16% during that period while stretching the period over a month that decreases to 13.20%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 51.88 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the BofA Securities which downgraded the stock as “Underperform” in its note to investors issued on October 30, 2024, recommending a price target of between $6 and $1 for it. H.C. Wainwright downgraded its recommendation for the stock as a “Neutral” from “Buy” on June 27, 2024 while assigning a price target range of $6-$1. JP Morgan also issued its recommendations for the stock as it downgraded the price target for the stock in the range of between $15 and $5.
Over the week, LYEL’s stock price is moving 27.04% up while it is 12.96% when we observe its performance for the past one month. Year-to-date it is -37.11% down and over the past year, the stock is showing a downside performance of -45.78%.
Currently, Lyell Immunopharma Inc’s total number of outstanding shares is 253.96M. Company’s return on investment (ROI) stands at -33.92% and return on equity (ROE) at -32.26%. Stock’s beta reads -0.29. Stock has a price to book (P/B) ratio of 0.55 while price to sale or P/S ratio amounts to 6246.40. Its return on asset (ROA) is -28.23% on average.
